rf-fullcolor.png

 

April 16, 2013
by Alexander Gaffney, RAC

All Generic Facilities Must Re-Register With FDA Starting Next Month, Agency Says

The US Food and Drug Administration (FDA) has announced a self-identification reporting period for the generic pharmaceutical industry during the upcoming fiscal year (FY), part of new requirements established under the FDA Safety and Innovation Act's (FDASIA) generic drug user fee provisions.

Background

In the lead-up to the 2012 passage of FDASIA, FDA's regulators had a problem: Increasing trends in globalization had resulted in many manufacturers of generic drugs and their active pharmaceutical ingredients locating themselves beyond US borders, making it difficult for FDA to inspect facilities and, worse, determine where drug products were being manufactured in many cases.

The Generic Drug User Fee Act (GDUFA) of FDASIA, modeled off of similar user fee provisions long enacted for pharmaceuticals and medical devices, aimed to remedy this situation in part by instituting two main requirements.

The first were user fees, levied on companies with pending applications, new abbreviated new drug applications (ANDAs), manufacturing facilities, and active pharmaceutical ingredient facilities, as well as yearly maintenance fees.

The second involved registration requirements, meant to ferret out companies and manufacturing facilities not yet known to FDA to make sure that regulators could both inspect those facilities and make sure they knew which ingredients and products they manufactured.

New Timeline

Now FDA has issued a notice to the generic pharmaceutical industry, instructing it on the requirements for the coming 2014 fiscal year.

That self-identification period will fall between 1 May 2013 and 1 June 2013, during which time all facilities, sites and organizations "identified in a generic drug submissions" will be required to submit, update or reconfirm all information reported to FDA under GDUA.

While many generic pharmaceutical companies have recently identified with FDA-the last deadline was in December 2012-FDA said that those companies will need to self-identify once again for FY2014 in the coming months.

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.